P. Shannon

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

Brian I. Rini, Mark N. Stein, P. Shannon et al. · Cancer · 2010 · 153 citations

A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors

Gary K. Schwartz, Stephanie Robertson, Angela Shen et al. · Journal of Clinical Oncology · 2009 · 95 citations

Raf Kinase Inhibitors, Pathology, Advanced Solid Tumors +17

The association of histological and radiological indicators of breast cancer risk

Stefan J. Urbanski, HM Jensen, G Cooke et al. · British Journal of Cancer · 1988 · 48 citations · Full text

Breast Oncology, Breast Cancer Risk, Cancer Pathology +11

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.

Ronald Feld, Ryszard Wierzbicki, P L Walde et al. · Journal of Clinical Oncology · 1992 · 45 citations

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

G. K. Schwartz, Salim Yazji, David S. Mendelson et al. · European Journal of Cancer Supplements · 2008 · 11 citations

Medicine, Receptor Tyrosine Kinase, Pharmacology +10